Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial

Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00612-6/abstract?dgcid=raven_jbs_etoc_feature_lanonc